| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
HeartSciences Inc.$2.75
+0.98 (+55.37%)
Market Cap
6.31 M
EPS
-4.93
P/E Ratio
-
Value Trade
39.26 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
638.58 K
Total Assets
7.55 M
Total Liabilities
4.90 M
Equity
2.65 M
D/E Ratio
12,345
3.13 %
Week
-6.6 %
1 Month
-30.04 %
3 Month
-35.92 %
6 Month
-99.47 %
5 Year
-99.47 %
All Time
Cash Data
Cash Position
3.40 M
Monthly Burn
643.00 K
Runway
2.2 mo
Burn Trend
StableSEC Filing
Mar 16, 2026
Overview
Volume
135.74 M
52 Week Range
1.77 - 6.47
% held by Insiders
2.34 %
% held by Institutions
6.77 %
Enterprise Value
6.78 M
Total Shares
3.19 M
Short %
1.43 %
Float Shares
3.03 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HSCS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HeartSciences Inc. (HSCS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
HSCS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HSCS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HSCS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HSCS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
HSCS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HSCSFortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets
HeartSciences has announced a business combination aimed at launching a vertically-integrated Zcash mining platform in public markets. This initiative emphasizes privacy and aims to enhance the company's market presence. The move is expected to attract investor interest and expand operational capabilities.
Read more →HSCSEuropean Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents
HeartSciences Inc. has been granted a European patent for its ECG-based assessment of diastolic function, enhancing its intellectual property portfolio to over 45 patents. This technology utilizes machine learning to estimate echocardiogram parameters from ECG data, potentially transforming cardiac disease assessment. The patent is effective in 19 European countries.
Read more →HSCSHeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
HeartSciences has launched MyoVista Insights version 1.3, featuring an AI-ECG Algorithm Marketplace that integrates third-party algorithms, starting with an FDA-cleared model from Bunkerhill Health. This platform aims to enhance clinical workflows and support earlier detection of heart failure. The company anticipates expanding the marketplace with more algorithms, positioning itself for significant revenue growth.
Read more →HSCSHeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
HeartSciences has announced a commercial agreement with North Shore Health to deploy its MyoVista Insights platform, aimed at improving ECG management. This marks the first deployment within the Cibolo Health network, which has endorsed the platform. The agreement is expected to enhance workflow efficiency and support AI integration in clinical practices.
Read more →HSCSHeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
HeartSciences Inc. has announced its first commercial revenue agreement with St. Vincent Health for the MyoVista Insights platform. This cloud-native, SaaS-based ECG management system aims to enhance clinical workflows and decision-making by integrating AI directly into routine procedures. The agreement signifies a major step for HeartSciences as it transitions into revenue-generating deployments, with expectations of securing additional contracts in the near future. The engagement with St. Vincent Health reflects the platform's potential to improve cardiac care.
Read more →HSCSHeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
HeartSciences Inc. is reminding shareholders to vote in the upcoming Annual Meeting on April 30, 2026. Shareholders can vote online before the deadline of April 29, 2026. The company emphasizes the importance of participation and provides resources for assistance. The meeting will be held virtually, allowing all eligible shareholders to engage.
Read more →HSCSHeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
HeartSciences has announced that its MyoVista Insights platform has received Epic Toolbox designation for the ECG Management System category. This designation signifies that MyoVista Insights meets Epic's recommended practices for integration, enhancing its usability within clinical workflows. The platform aims to improve workflow efficiency and support clinical decision-making through advanced AI integration.
Read more →HSCSHeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
HeartSciences Inc. will present at the Investor Summit Group Virtual Conference on March 25, 2026. CEO Andrew Simpson is set to outline the company's business strategy and growth catalysts during the presentation. The event aims to enhance investor engagement and visibility in the capital markets, followed by one-on-one meetings with qualified investors.
Read more →HSCSHeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
HeartSciences reported its fiscal third quarter 2026 results, highlighting advancements in its MyoVista Insights platform and the submission of the MyoVista wavECG device to the FDA for clearance. The company is focused on establishing reference sites and generating initial revenues, with positive feedback from early adopters. A significant upgrade to the platform was released ahead of the ACC Annual Scientific Session.
Read more →HSCSUniversity of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
HeartSciences has partnered with the University of the West of England to implement its MyoVista Insights platform and MyoVista wavECG device for ECG education. This initiative aims to train future cardiac scientists and enhance the UK's cardiac diagnostic capabilities. The collaboration will also facilitate real-world validation of the technology in educational settings, supporting NHS workforce goals.
Read more →HSCSCibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
HeartSciences has been designated by Cibolo Health as the endorsed ECG management platform for its network of 123 independent hospitals. This collaboration aims to modernize ECG workflows, improving efficiency and clinical decision-making. MyoVista Insights will provide secure, cloud-based ECG data management, integrating AI algorithms into routine practice. This partnership aligns with Cibolo Health's mission to enhance care delivery while managing costs.
Read more →HSCSHeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
HeartSciences Inc. reported its fiscal second quarter 2026 financial results, highlighting progress in the commercialization of its MyoVista Insights healthcare IT platform. The company submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance, marking a significant regulatory milestone. Despite these advancements, HeartSciences reported no meaningful revenue for the quarter and has limited cash reserves.
Read more →HSCSHeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
HeartSciences has submitted its MyoVista wavECG device for FDA 510(k) clearance, aiming to enhance ECG functionality with AI integration. The decision to separate the submissions for the device and its AI-ECG software is intended to streamline the regulatory process. The company is also advancing its commercialization strategy and engaging in discussions with healthcare institutions.
Read more →HSCSHeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
HeartSciences has launched MyoVista Insights version 1.1, an upgraded ECG management platform that enhances clinical interpretation and workflow efficiency. The cloud-native system is designed to be device agnostic, allowing for greater flexibility in ECG data management. CEO Andrew Simpson highlighted strong validation from early users and ongoing discussions with major healthcare institutions for future deployments.
Read more →HSCSHeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
HeartSciences Inc. announced its financial results for the first quarter of fiscal 2026, highlighting significant progress including FDA Breakthrough Device Designation and the launch of MyoVista Insights. Despite reporting no meaningful revenue, the company has strengthened its balance sheet through additional funding. Management expresses optimism about achieving regulatory clearances and initial revenues in 2026.
Read more →HSCSHeartSciences Announces Conference Participation and Investor Webinar
HeartSciences Inc. announced its participation in several virtual events in August 2025, including an Investor Webinar and the Emerging Growth Conference 85. These events aim to introduce the company's AI-powered ECG technology and provide updates to investors. The Investor Webinar is scheduled for August 20, 2025, at 2:00 PM ET, followed by a presentation at the conference at 3:10 PM ET.
Read more →HSCSHeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
HeartSciences Inc. announced its fiscal 2025 financial results and a business update showcasing strategic advancements in AI-powered ECG technologies. The company's MyoVista Insights platform, which integrates AI for enhanced ECG management, began rollout in May 2025, with plans for an FDA submission in 2026. HeartSciences has also developed the MyoVista wavECG device, nearing FDA 510(k) submission. Despite these advancements, the company reported no meaningful revenue for the fiscal year and has limited cash reserves.
Read more →HSCSHeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
HeartSciences has received FDA Breakthrough Device designation for its MyoVista Insights AI-ECG algorithm, which detects aortic stenosis. This algorithm, developed using advanced deep learning techniques, can identify the condition up to 24 months earlier than current methods. The technology will integrate with hospital EHR systems, enhancing accessibility and potentially improving patient outcomes.
Read more →HSCSFoundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
HeartSciences Inc. has been granted a foundational patent by the USPTO for estimating echocardiography parameters using ECG, enhancing its intellectual property portfolio. This patent marks the 10th US patent and 34 international patents for the company, underscoring its position in the AI-ECG field. The company aims to improve healthcare through innovative ECG technology.
Read more →HSCSHeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
HeartSciences Inc. has signed its first commercial customer, Westcliffe Health Innovations, for its MyoVista Insights platform. This partnership aims to enhance access to ECGs in the UK, particularly within the NHS. MyoVista Insights is a cloud-native ECG management system designed to improve clinical decision-making and operational efficiency. The collaboration marks a significant milestone in HeartSciences' commercial journey.
Read more →HSCSHeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
HeartSciences Inc. announced that CEO Andrew Simpson will present at the Emerging Growth Conference 82 on May 21, 2025. The presentation will focus on the company's AI-powered ECG technology aimed at improving heart disease detection. Attendees can register for the live event or access an archived version later.
Read more →HSCSHeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results Southlake, TX
HeartSciences reported its third-quarter fiscal 2025 financial results, highlighting significant advancements in its AI-ECG technology. The company is preparing for FDA submissions for its MyoVista wavECG device and has completed Phase 1 of the MyoVista Insights platform. Additionally, with CMS establishing reimbursement for AI-ECG, HeartSciences sees potential for commercialization and broader adoption of its technology in healthcare settings. Financial results revealed no revenue, underscoring the company's funding needs as it advances its innovative solutions.
Read more →HSCSHeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
HeartSciences Inc. will host a live investor webinar on May 14, 2025, featuring CEO Andrew Simpson. The session will focus on the company's AI-powered ECG platform aimed at improving heart disease detection. Investors will learn about the company's mission and current investment opportunities, including a Regulation A offering.
Read more →HSCSHeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
HeartSciences Inc. has appointed Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to its Scientific Advisory Board. These appointments reflect the company's dedication to advancing AI-powered ECG technology for early heart disease detection. The new members bring extensive expertise in cardiology and digital medicine, positioning HeartSciences for significant advancements in cardiac care.
Read more →HSCSHeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
HeartSciences has launched the MyoVista Insights platform, an AI-powered ECG management system designed to enhance clinical decision-making and healthcare IT efficiency. The platform integrates AI-ECG algorithms and offers features that streamline workflows and reduce costs. It is vendor-agnostic and aims to improve the clinical utility of ECGs, facilitating earlier detection of heart disease.
Read more →HSCSHeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
HeartSciences Inc. provided a business update and reported its financial results for the third quarter of fiscal 2025, highlighting advancements in AI-powered ECG technology. The company aims to modernize the ECG industry through its innovative MyoVista® products and has a clear roadmap for FDA submissions. Significant progress has been made in discussions with test sites and collaborations for clinical validation and algorithm development. Despite facing no revenues during Q3 FY2025, the establishment of reimbursement for AI-ECG signals a promising commercial landscape.
Read more →HSCSHeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
HeartSciences Inc. has engaged Integrous Communications to strengthen its investor relations efforts. The partnership aims to enhance communication with the investment community and effectively convey the company's growth strategies. HeartSciences is focused on using AI technology to improve ECG clinical utility and aims for future FDA clearance of its product candidate, MyoVista. This collaboration is expected to bolster investor engagement as the company advances its innovative cardiac screening solutions.
Read more →HSCSHeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
HeartSciences Inc. reported its financial results for the second quarter of fiscal 2025, highlighting major advancements in its AI-ECG technologies, including the MyoVista Insights platform and the MyoVista wavECG device. The company aims to complete Phase 1 development by the end of 2024, with plans for a FDA submission in early 2025. Despite positive developments, HeartSciences reported no revenues during the quarter and holds limited cash reserves. The advancement in regulatory approvals and reimbursement policies positions HeartSciences for potential market impact in the AI-driven ECG space.
Read more →HSCSHeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
HeartSciences announced that the Centers for Medicare & Medicaid Services (CMS) has approved reimbursement for its AI-ECG technology under the 2025 Hospital Outpatient Prospective Payment System. This includes the MyoVista wavECG and MyoVista Insights algorithms, pending FDA clearance. The reimbursement rate is expected to be $125. The CEO emphasized this development as a major step toward commercializing their products and highlighted the significant market potential for ECG technologies.
Read more →HSCSHeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
HeartSciences, also known as Heart Test Laboratories, will participate in the 2024 Maxim Healthcare Virtual Summit from October 15 to 17, 2024. CEO Andrew Simpson is set to engage in a fireside chat with analyst Allen Klee on October 17th. The company focuses on advancing ECG technology through AI to enhance cardiac disease detection and improve clinical care pathways. HeartSciences is also working on its first product candidate, the MyoVista® wavECG™, aimed at providing diagnostic information while maintaining conventional ECG capabilities.
Read more →HSCSHeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
HeartSciences announced the closure of a non-dilutive financing round, generating $1.9 million in net proceeds, which bolsters its capital runway as it approaches FDA submissions. The company has also extended an existing loan, increasing its financial foundation for future growth. HeartSciences aims to enhance ECG technology with AI, providing diagnostic capabilities that can improve heart disease detection. This financial move is a strategic step toward achieving the company's commercial objectives.
Read more →HSCSHeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
HeartSciences has reported a positive business update alongside its financial results for the first quarter of fiscal 2025. The company has made significant advancements in its MyoVista wavECG device and Insights cloud platform, showcasing potential for innovative AI-ECG solutions. Despite no revenue generated during the quarter, the company extended its cash runway through successful non-dilutive financing efforts. They remain focused on regulatory submissions, aiming for FDA approvals within the upcoming year.
Read more →HSCSHeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
HeartSciences has reported positive developments in its fiscal 2024 results, indicating significant progress towards its AI-ECG solutions aimed at early heart disease detection. The company has a robust financial position and plans to submit FDA filings for its MyoVista Insights platform and MyoVista wavECG device. It has secured valuable AI-ECG algorithms from Mount Sinai, while also receiving encouraging feedback on its beta platform. Challenges include regulatory delays and technical issues that have arisen during development and testing.
Read more →HSCSHeartSciences Selected to Demonstrate MyoVista wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
HeartSciences has been selected to demonstrate its MyoVista wavECG technology at the United Nations General Assembly Digital Health Symposium in September 2024. This selection highlights the technology's potential to drive radical transformation in healthcare. The recognition follows a demonstration at the International Digital Health Summer School 2024, emphasizing the need for advanced technologies in preventative healthcare. HeartSciences aims to improve the early detection of heart disease through AI-powered ECG technology.
Read more →HSCSHeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
HeartSciences has announced that it has received a notice of allowance from the USPTO for a patent related to AI-driven ECG assessments of left and right ventricular dysfunction. This development aims to enhance early detection and diagnostic capabilities for heart disease, a critical public health concern. The patent strengthens HeartSciences' intellectual property portfolio within the AI-ECG space, supporting its commitment to improving healthcare outcomes through innovative technology. CEO Andrew Simpson emphasized that this patent expands the company's offerings and value to stakeholders.
Read more →HSCSHeartSciences Regains Compliance with Nasdaq Listing Requirements
HeartSciences, operating under the ticker HSCS, has announced that it has regained compliance with Nasdaq listing requirements as of June 3, 2024. This notice from Nasdaq allows the company to continue trading on the stock exchange without the threat of delisting, as the scheduled hearing regarding its compliance has been cancelled. HeartSciences is focused on enhancing ECG technology using AI, aiming to provide better cardiac screening tools in various healthcare settings.
Read more →HSCSHeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
HeartSciences has announced the granting of its Indian patent for its AI-ECG technology, enhancing its international patent portfolio which now totals 44 patents. The company highlights the urgent need for improved heart disease screening in India, the world's most populated country, where cardiovascular diseases are a leading cause of death. CEO Andrew Simpson stated that this patent reinforces their position in the AI-ECG market. The company is focused on making ECG technology more effective and accessible in various clinical settings worldwide.
Read more →HSCSHeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
HeartSciences has been granted a patent by the European Patent Office for its AI-powered ECG technology that enables diastolic dysfunction assessment. This capability aims to improve the early detection of heart disease, which is a significant advancement over traditional echocardiography methods. The company highlights that millions of ECG tests are performed weekly, and the integration of cardiac dysfunction detection could enhance healthcare providers' effectiveness. The patent contributes to HeartSciences' growing portfolio of IP, positioning it well within the expanding ECG market, projected to reach $25 billion annually by 2032.
Read more →HSCSHeartSciences to Present at the LD Micro Invitational XIV Conference
HeartSciences, a medical technology company, announced that its CEO, Andrew Simpson, will present at the LD Micro Invitational XIV Conference on April 9, 2024. The company focuses on utilizing AI to improve the clinical utility of ECGs and enhance heart disease detection. HeartSciences is working towards FDA clearance for its MyoVista® wavECG™ product, which aims to provide diagnostic information that traditionally requires cardiac imaging. A webcast of the presentation will be accessible via the company's investor relations website.
Read more →HSCSHeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
HeartSciences announced a podium presentation at the 18th World Congress of Anesthesiologists in Singapore, detailing a study on its MyoVista wavECG device for detecting left ventricular diastolic dysfunction (LVDD) in preoperative patients. The study reported that the MyoVista tool could serve as an effective screening method with 100% sensitivity, potentially minimizing unnecessary referrals for echocardiography. CEO Andrew Simpson highlighted the MyoVista's significant utility for cardiovascular medicine, with plans for its commercialization. The findings reinforce the device's promising role in managing heart disease risk before surgeries.
Read more →HSCSHeartSciences Reports Third Quarter Fiscal 2024 Financial Results
HeartSciences reported its third-quarter fiscal 2024 financial results and provided an update on its business progress. The company highlighted a strategic shift to a broader AI-ECG portfolio and secured licenses from Mount Sinai, enhancing its technological foundation. Financially, HeartSciences improved its equity position significantly, reaching $8.6 million from a previous deficit. Additionally, the firm anticipates quicker FDA clearance for its MyoVista device, bolstered by recent clinical validation advancements.
Read more →HSCSHeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
HeartSciences has announced a peer-reviewed study published in Cardiovascular Diabetology that highlights the effectiveness of its MyoVista technology in screening for asymptomatic left ventricular dysfunction in patients with type 2 diabetes. The study found that the AI-driven MyoVista model significantly outperforms traditional methods like NT-proBNP and the ARIC HF risk score. This advancement may potentially improve heart disease detection and treatment in diabetic patients, addressing a significant health concern that affects millions globally.
Read more →HSCSHeartSciences Announces Canada Patent Grant Covering MyoVista Wavelet Technology
HeartSciences has announced the granting of a patent in Canada for its MyoVista wavelet technology, which aims to improve early detection of heart disease using AI-powered ECGs. The patent, granted by the Canadian Intellectual Property Office, adds to the company's extensive portfolio of international patents and registrations. CEO Andrew Simpson highlighted the transformative potential of AI-ECG technology, aiming to not only improve clinical utility but also reduce costs in healthcare. This development positions HeartSciences strongly within the rapidly expanding ECG market, projected to reach $25 billion by 2032.
Read more →HSCSHeartSciences Adds Key Advisor to its Scientific Advisory Board
HeartSciences has appointed Dr. Partho Sengupta to its Scientific Advisory Board, bringing extensive experience and a history of innovation in cardiology. Dr. Sengupta has authored multiple peer-reviewed publications and has received numerous awards for his contributions to cardiovascular research. He expressed excitement about leveraging AI technology to advance the field of cardiology, indicating that this collaboration could lead to significant improvements in ECG diagnostics. This strategic addition aims to strengthen HeartSciences' capabilities in utilizing AI for early heart disease detection.
Read more →HSCSHeartSciences Expands its Scientific Advisory Board
HeartSciences has appointed Dr. Jordan B. Strom to its Scientific Advisory Board, bolstering its efforts in the deployment of AI-powered ECG technology. Dr. Strom, an experienced cardiologist, will assist the company as it prepares for FDA submission of its MyoVista device, a tool aimed at enhancing early detection of heart disease. His extensive background in artificial intelligence and medical devices positions him as a valuable asset for the company in achieving its objectives in cardiac care innovation.
Read more →HSCSHeartSciences Appoints New Scientific Advisory Board Member
HeartSciences has appointed Dr. Benjamin Glicksberg to its Scientific Advisory Board, enhancing its focus on AI-driven ECG technology for heart disease detection. Dr. Glicksberg brings substantial expertise from his previous roles, including leadership in the AI-ECG program at Mount Sinai. The company aims to achieve significant milestones in 2024, including FDA clearance for its MyoVista device and developing a cloud platform to deliver AI-ECG algorithms. This appointment is expected to bolster HeartSciences' mission of improving clinical diagnostic capabilities.
Read more →HSCS(2) The issuances of warrants to purchase up to 240,000 shares of common stock, at an exercise price of $0.17 per share, to a consultant of the Company as consideration for services rendered. (3) The issuance to Mount Si
Heart Test Laboratories, Inc. (HSCS) has released its pro forma balance sheet showing increases in total assets primarily due to new capital raised through equity offerings. Recent actions include the issuance of significant shares to various parties, such as consultants and to settle notes. While the company’s current assets are bolstered, it continues to face substantial accumulated deficits and high current liabilities, which raises potential liquidity concerns. These updates were filed with the SEC as part of their quarterly report.
Read more →HSCSHeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
HeartSciences announced the results of its Annual Meeting of Shareholders, where all proposals were approved except for Proposal 7 regarding quorum requirements for future meetings. CEO Andrew Simpson expressed gratitude for shareholder support. Proposal 7, lacking sufficient votes for approval, will lead to an adjournment of the meeting to solicit additional votes, scheduled for February 15, 2024. Shareholders are encouraged to participate in the upcoming vote to ensure the proposal's passage.
Read more →HSCSHeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
Heart Test Laboratories, Inc., operating as HeartSciences, is reminding shareholders to vote in the upcoming 2023 Annual Meeting scheduled for January 17, 2024. All shareholders of record as of November 20, 2023, are eligible to participate and vote. The company emphasizes the importance of reading the definitive proxy statement filed with the SEC for detailed information and encourages all shareholders to vote their proxies. HeartSciences aims to enhance ECG diagnostic accuracy through AI technology, which could improve healthcare delivery.
Read more →HSCSHeartSciences Reports Second Quarter Fiscal 2024 Financial Results
HeartSciences has reported its financial results for Q2 of fiscal 2024, highlighting several key achievements, including new agreements with Mount Sinai and the shift to a cloud-based, algorithm portfolio. The company has received FDA confirmation for a more streamlined 510(k) submission process for its MyoVista device, enhancing its market potential. Despite positive developments, HeartSciences continues to grapple with financial challenges, reporting no significant revenues and a deficit in shareholders' equity. Nevertheless, the leadership remains optimistic about future growth opportunities within the AI-ECG sector.
Read more →HSCSHeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
HeartSciences has received FDA confirmation to transition the clearance pathway for its MyoVista wavECG device to a standard 510(k) submission. This change aims to streamline and accelerate the approval process for the AI-driven ECG technology. The CEO highlighted that the shift will require some adjustments but is expected to lead to faster overall clearance. The company is on track for FDA submission in the first half of 2024, marking a significant step forward in heart disease detection capabilities.
Read more →HSCSHeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
HeartSciences has finalized license agreements with the Icahn School of Medicine at Mount Sinai to develop AI-powered ECG algorithms for cardiovascular disease detection. This partnership not only strengthens HeartSciences' position in medical technology but also aligns with a new FDA classification aimed at expediting the regulatory process for these algorithms. With a focus on early diagnosis and improved patient care, HeartSciences plans to deploy these innovations using a cloud-based platform compatible with existing ECG devices.
Read more →HSCSHeartSciences’ MyoVista wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
HeartSciences has announced that its MyoVista wavECG technology has been selected by Cardiact Ltd for a heart screening program targeting members of the Garda Síochána in Ireland. This initiative aims to enhance early detection of heart disease and will commence on November 27, 2023. The program includes the establishment of a new referral pathway to cardiology, indicating a broader commitment to preventive healthcare. CEO Andrew Simpson expressed optimism about the growing acceptance of AI in ECG technology, which he believes presents significant commercial opportunities for HeartSciences.
Read more →HSCSHeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments
HeartSciences has announced significant advancements, including a transformative agreement with Icahn Mount Sinai for the development of AI-based ECG algorithms. They have also filed an FDA Pre-Submission Request to switch from a De Novo to a 510(k) submission process, which is expected to expedite their product clearance. The company plans to discuss these developments in a conference call on October 25, 2023. These moves position HeartSciences favorably within the cardiovascular diagnostics landscape, leveraging advanced AI technology.
Read more →HSCSHeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
HeartSciences has announced the issuance of two new patent allowances from Brazil and the UAE, expanding its international patent portfolio to a total of 33 patents globally. This development is seen as a strategic move to enhance the company's AI-powered ECG technology, which is designed for better detection of heart disease. The CEO highlighted that these advancements are expected to drive significant growth in the ECG market, which could reach $25 billion annually. Additionally, partnerships with top hospitals, like Mount Sinai, indicate plans for broader implementation of their technology in clinical practice.
Read more →HSCSHeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.
HeartSciences, an AI-focused medical technology company, is set to present at the Maxim Group's Virtual Tech Conference on September 27, 2023. CEO Andrew Simpson will discuss how the company is transforming ECGs to improve early detection of heart disease. The company's product, MyoVista®, aims to enhance the clinical utility of ECGs, particularly in frontline healthcare settings. HeartSciences' business model includes the proprietary electrodes necessary for the device's operation, enhancing its economic viability.
Read more →HSCSHeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
HeartSciences has entered into definitive agreements with the Icahn School of Medicine at Mount Sinai to commercialize AI-powered electrocardiographic algorithms. This collaboration aims to leverage Mount Sinai's extensive ECG data to enhance the screening and diagnosis of cardiovascular diseases. HeartSciences also announced plans for a cloud-based platform, aiming to provide AI solutions globally. The partnership is a significant step for HeartSciences in advancing its MyoVista® wavECG™ device and improving early heart disease detection.
Read more →HSCSHeartSciences Reports First Quarter Fiscal 2024 Financial Results
HeartSciences reported its financial results for Q1 fiscal 2024, marking significant advancements in its operations and partnerships. Key milestones include engaging distributors in the Nordic region and India, as well as a collaborative study in Ireland. However, the company reported no revenues and low cash reserves, highlighting financial challenges. CEO Andrew Simpson emphasized the potential of the MyoVista technology to revolutionize ECG diagnostics and target FDA clearance by late 2023.
Read more →HSCSHeartSciences to Present at the Gilmartin Group Emerging Growth Showcase
HeartSciences, an AI-based medical technology company, announced participation in the Gilmartin Group Emerging Growth Showcase on September 21, 2023. CEO Andrew Simpson will engage in a fireside chat discussing HeartSciences' innovations, particularly its MyoVista® wavECG™ product aimed at improving ECG utility in clinical settings. The company is focused on transforming the accuracy of ECGs to aid in early heart disease detection. Investors and interested parties can access the live webcast through HeartSciences' website.
Read more →HSCSHeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards
Heart Test Laboratories, Inc., also known as HeartSciences, has been recognized as the Electrocardiography Advancement Specialists of the Year 2023 – USA by the Global Health & Pharma Excellence Awards. This accolade is in recognition of the company's pioneering work in utilizing artificial intelligence to enhance electrocardiography. The award reflects HeartSciences' commitment to improving cardiac care through their innovative MyoVista® wavECG™ Technology, which aims to transform the clinical usefulness of ECGs in healthcare settings. The CEO expressed that AI technology is poised to revolutionize cardiac care.
Read more →HSCSHeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India
HeartSciences has entered into a distribution agreement with MedPhy Technologies in Mumbai, India, aimed at enhancing the availability of its AI-based MyoVista® Wavelet ECG (wavECG™) technology. This partnership is expected to improve early detection of heart diseases, addressing a significant health issue in India, which sees a high number of cardiovascular-related deaths. MedPhy Technologies will play a key role in importing and distributing the MyoVista® across the country, thus potentially providing better diagnostic resources to healthcare professionals. With the deployment of this technology, HeartSciences aims to revolutionize the ECG market and enhance patient outcomes in India.
Read more →HSCSHeartSciences Signs Distribution Agreement with FJ Medical, Denmark
HeartSciences has entered into a distribution agreement with FJ Medical based in Denmark, appointing them as the distributor for its MyoVista wavECG technology in the Nordic countries. The agreement mandates the stocking of MyoVista devices and related supplies, ensuring prompt technical service to local customers. This strategic move is aimed at bolstering HeartSciences' commercialization efforts in the region and leverages existing physician relationships. The MyoVista device is designed to improve ECG diagnostic capabilities, which could significantly impact heart disease detection.
Read more →HSCSHeartSciences’ MyoVista wavECGTM Selected to be used in Irish Heart Screening Evaluation
HeartSciences announced that its MyoVista wavECG has been chosen for a heart screening evaluation program in Dublin, Ireland. The study, conducted in conjunction with PanaceaFlo Ltd, aims to establish a cardiovascular risk screening program, initially involving 250 participants, including police officers. If successful, the program may expand nationally as part of Ireland's public health initiative focusing on preventative care. The company's advanced AI technology could significantly improve early detection of heart disease, alleviating pressure on healthcare systems.
Read more →HSCSHeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio
HeartSciences has received a notice of patent allowance from the European Patent Office, expanding its portfolio to 41 patents, including 9 in the US. This new patent enhances ECG technology by allowing quantification of key echocardiographic measures using AI methods, a capability previously unattainable with standard ECGs. The CEO highlighted the significant potential for improving early heart disease detection through their MyoVista® device, which could transform cardiac health screening across various clinical settings.
Read more →HSCSHeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results
HeartSciences, an AI-based medical technology company, provided a business update and reported fiscal 2023 results, highlighting key milestones achieved in the past year. Notably, the company completed patient enrollment for its pivotal MyoVista study and is preparing for FDA submission later this year. The company has expanded its patent portfolio significantly, with 40 patents granted, and entered a collaboration with Rutgers University to enhance its AI ECG algorithms. HeartSciences aims to revolutionize cardiac care and commercialize its MyoVista technology pending regulatory approvals.
Read more →HSCSHeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine
HeartSciences, operating under Heart Test Laboratories, has been named one of the Top 10 healthcare artificial intelligence solutions providers for 2023 by Healthcare Tech Outlook Magazine. This recognition highlights the company's MyoVista device which focuses on improving early detection of heart disease through AI-enhanced ECG technology. CEO Andrew Simpson expressed optimism regarding AI's role in enhancing cardiology outcomes and indicated plans for an FDA submission following their pivotal study. The article reflects on the growing impact of AI in healthcare, with increasing expenditure predicted for AI applications.
Read more →HSCSHeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG
HeartSciences has announced the completion of patient enrollment for its pivotal study focusing on the MyoVista wavECG, aimed at FDA De Novo submission. This multi-center study, involving over 600 patients, targets the validation of an AI algorithm for detecting impaired left ventricular relaxation, a key early indicator of heart disease. With patient enrollment finalized, the collected data will undergo analysis to support their regulatory submission. The study represents a significant advancement in the integration of artificial intelligence in cardiac diagnostics.
Read more →HSCSHeartSciences to Participate at the Inaugural EF Hutton Global Conference
HeartSciences, a company focused on AI-based ECG technology, announced its participation in the EF Hutton Global Conference scheduled for May 10-11, 2023, in New York City. CEO Andrew Simpson will hold one-on-one meetings with attendees, offering insights into the company's advancements in heart disease detection. The event signifies a strategic opportunity for HeartSciences to enhance its visibility and partnerships within the healthcare sector. With the increasing importance of AI in medical technology, the conference presents a platform for sharing significant developments in electrocardiology.
Read more →HSCSHeartSciences to Participate in The Benchmark Company’s Virtual Individual Investor Healthcare Conference
Heart Test Laboratories, Inc., doing business as HeartSciences, will have its CEO, Andrew Simpson, present at The Benchmark Company’s Virtual Individual Investor Healthcare Conference on May 4, 2023. The presentation aims to showcase the company’s advancements in AI ECG technology, which seeks to enhance the screening process for heart disease. HeartSciences focuses on addressing the diagnostic gap in this field, promoting earlier and better referral decisions for at-risk patients.
Read more →HSCSHeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023
Heart Test Laboratories, Inc., operating as HeartSciences, will present at the Planet MicroCap Showcase in Las Vegas from April 25 to 27, 2023. CEO Andrew Simpson is scheduled to deliver a corporate overview on April 26. The company focuses on enhancing ECG screening capabilities through AI technology, aiming to improve cardiac assessments in clinical settings. The MyoVista® wavECG device is its primary product candidate seeking FDA clearance.
Read more →HSCSHeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results
HeartSciences, a medical technology company focused on enhancing ECG screening through AI, provided a business update and reported its financial results for Q3 2023. The company has made significant strides, including a collaboration with Rutgers University and an expanded patent portfolio. CEO Andrew Simpson emphasized ongoing efforts toward FDA De Novo clearance for their MyoVista® device, which aims to improve the early detection of cardiac dysfunction. Despite reporting no meaningful revenue during the quarter, HeartSciences remains optimistic about its financial stability and future prospects.
Read more →HSCSHeartSciences CEO Invited as Featured Guest on The Big Biz Show, February 7 at 11:45 a.m. Pacific Time
Heart Test Laboratories, Inc. (HeartSciences) announced that its CEO, Andrew Simpson, will be a featured guest on the Big Biz Show on February 7, 2023. The program is nationally syndicated and will discuss the MyoVista® device, which uses artificial intelligence for early detection of heart disease. HeartSciences aims to enhance the usefulness of ECGs in clinical settings as part of their mission to improve healthcare. Simpson's participation is expected to raise awareness about the company's innovative approach to cardiac screening.
Read more →HSCSHeartSciences Granted Key Israeli International Patent for its MyoVista Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease
HeartSciences has secured a new international patent in Israel for its MyoVista technology, which utilizes artificial intelligence to improve the early detection of heart disease through enhanced ECG capabilities. The MyoVista offers traditional ECG information alongside AI-driven insights into cardiac dysfunction, expanding its clinical applications. With a total of 40 patents granted, HeartSciences is positioning itself as a leader in medical technology innovation, focusing on significant advancements in cardiac screening. The company plans to leverage its intellectual property as a competitive advantage as it moves toward commercialization of its products.
Read more →HSCSHeartSciences Announces Further Internationalization of its Patent Portfolio
HeartSciences has received a new patent in South Korea, increasing its total to 39 patents internationally and enhancing its intellectual property portfolio. The patent protects the MyoVista®, a 12-lead electrocardiograph that employs AI to detect cardiac dysfunction. CEO Andrew Simpson highlighted the potential of the MyoVista® to change the landscape of heart health screenings globally, especially considering the high incidence of cardiovascular disease. This move is part of the company's strategy to secure competitive advantage in key markets as they work towards commercialization.
Read more →HSCSHeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
HeartSciences' CEO, Andrew Simpson, will participate in the Healthcare IT Virtual Conference on January 25, 2023. The conference, presented by Maxim Group LLC and hosted by M-Vest, will feature a fireside chat focused on the company's innovative ECG technology that incorporates artificial intelligence. HeartSciences aims to enhance the diagnostic capabilities of ECGs, particularly through its MyoVista device, which is pending FDA clearance. This initiative marks a significant step for the company in redefining cardiac screening processes at the point of care.
Read more →HSCSHeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive
HeartSciences has appointed David R. Wells as a new member of its Board of Directors, effective December 28, 2022. Wells brings over 30 years of financial management expertise, particularly in the medical technology sector, which will be beneficial as the company progresses towards FDA clearance for its innovative ECG technology. He has a strong background in financing startups and managing initial public offerings, positioning HeartSciences well for its upcoming commercialization efforts. Patrick Kanouff has resigned from the Board contemporaneously with Wells's appointment.
Read more →HSCSHeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results
Southlake, Texas, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screeni
Read more →HSCSHeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms
Southlake, Texas, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screeni
Read more →HSCSHeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022
Southlake, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screeni
Read more →HSCSHeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screeni
Read more →HSCSHeartSciences’ MyoVista Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
Southlake, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screeni
Read more →HSCSHeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista ECG
Southlake, Texas, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screeni
Read more →HSCSHeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook Magazine
Southlake, Texas, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screeni
Read more →HSCSHeartSciences Announces Major Milestone with the Issuance of CPT Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction
SOUTHLAKE, Texas, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screeni
Read more →HSCSHeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
Southlake, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to sig
Read more →HSCSHeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartScience
Read more →HSCSHeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital
Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clin
Read more →HSCSHeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Southlake, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to sig
Read more →HSCSHeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results
MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year Completed IPO in June 2022 with Approximately $6.375M of Gross Proceeds Listed on NASDAQ Capital Market under Ticker HSCS Southlake, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- – Heart Test Laboratories, Inc. d/b/a
Read more →HSCSHeartSciences CEO to Participate in the Benzinga All Access Event on July 15th
Southlake, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- HeartSciences (NASDAQ: HSCS; HSCSW) (“Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness,
Read more →HSCSHeart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing Southlake, Texas
Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing Southlake, Texas, June 15, 2022 (GLOBE NEWSWIRE) Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) ( HeartSciences or the Company ), a medical technology company focu
Read more →Competitive Position
How HSCS ranks across every disease it competes inCompetitive Position is a premium feature
See how HSCS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial